

ANDA 74-504

June 28, 2000

TEVA Pharmaceuticals USA
Attention: Deborah A. Jaskot
U.S. Agent for: Novopharm Limited
1510 Delp Drive
Kulpsville, PA 19443

Dear Madam:

This is in reference to your abbreviated new drug application dated June 9, 1994, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Tamoxifen Citrate Tablets USP, 10 mg (base) and 20 mg (base).

Reference is also made to your amendments dated April 27, April 28, May 4, and May 29, 2000.

We have completed the review of this abbreviated application and have concluded that, based upon the information you have presented to date, the drug is safe and effective for use as recommended in the submitted labeling. Therefore, the application is **tentatively approved**. This determination is based upon information available to the Agency at this time, (i.e., information in your application and the status of current good manufacturing practices (CGMPs) of the facilities used in the manufacture and testing of the drug product), and is subject to change on the basis of new information that may come to our attention.

The reference listed drug product (RLD) upon which you have based your application, Nolvadex Tablets of AstraZeneca Pharmaceuticals, L.P., is subject to a period of patent protection which expires on August 20, 2002 (U.S. Patent No. 4,536,516, the "516" patent"). Your application contains a patent certification under Section 505(j)(2)(A)(vii)(IV) of the Act stating that the patent is invalid. You have informed the agency that Zeneca Inc. initiated a civil patent infringement suit against Novopharm Limited in the United

States District Court for the District of Maryland (Civil Action # S95-163), and that Zeneca Inc. prevailed. You have also informed the agency that Zeneca Inc. prevailed in the United States Court of Appeals for the Federal Circuit (96-1364). As a result, you revised your patent certification to a Paragraph III Certification to the '516 patent under Section 505(j)(2)(A)(vii)(III) of the Act and stated that Novopharm Ltd. will not market this drug product prior to the expiration of this patent. Therefore, final approval of your application may not be made effective pursuant to 21 U.S.C. 355(j)(5)(B)(ii) of the Act until the period has expired, i.e., currently August 20, 2002.

Because the Agency is granting a tentative approval for this application, please submit an amendment at least 60 days (but not more than 90 days) prior to the date you believe your application will be eligible for final approval. This amendment should identify changes, if any, in the conditions under which the product was tentatively approved, and should include updated information such as final-printed labeling, chemistry, manufacturing, and controls data as appropriate. An amendment should be submitted even if none of these changes were made. This submission should be designated clearly in your cover letter as a MINOR AMENDMENT. In addition to this amendment, the Agency may request at any time prior to the final date of approval that you submit an additional amendment containing the information described above.

Failure to submit either or, if requested, both amendments may result in rescission of the tentative approval status of your application, or may result in a delay in the issuance of the final approval letter.

Any significant changes in the conditions outlined in this abbreviated application as well as changes in the status of the manufacturing and testing facilities' compliance with current good manufacturing practices (CGMPs) are subject to Agency review before final approval of the application will be made.

Please note that this drug product may not be marketed without final Agency approval under Section 505 of the Act. The introduction or delivery for introduction into interstate

commerce of this drug product before the final approval date is prohibited under Section 501 of the Act and 21 U.S.C. 331(d). Also, until the Agency issues the final approval letter, this drug product will not be deemed approved for marketing under 21 U.S.C. 355 and will not be listed in the "Approved Drug Products with Therapeutic Equivalence Evaluations" list (the "Orange Book"), published by the Agency. Should you believe that there are grounds for issuing the final approval letter prior to August 20, 2002, you should amend your application accordingly.

At the time you submit any amendments, you should contact Michelle Dillahunt, Project Manager, at (301) 827B5848, for further instructions.

Sincerely yours,

Gary Buehler
Acting Director
Office of Generic Drugs
Center for Drug Evaluation and

Research